IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.04) per share. The company reported quarterly sales of $295.000 thousand which beat the analyst consensus estimate of $193.000 thousand by 52.85 percent. This is a 77.71 percent increase over sales of $166.000 thousand the same period last year.
IGC Pharma Q4 2024 GAAP EPS $(0.04), Sales $295.000K Beat $193.000K Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.